𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Therapeutic Considerations in Patients with Metastatic Renal Cell Carcinoma Previously Treated with Antiangiogenic Therapies

✍ Scribed by Saby George; Brian I. Rini

Book ID
115075938
Publisher
CIG Media Group, LP.
Year
2006
Tongue
English
Weight
241 KB
Volume
5
Category
Article
ISSN
1558-7673

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 2 trial of talactoferrin in previo
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
✍ Eric Jonasch; Walter M. Stadler; Ronald M. Bukowski; Teresa G. Hayes; Atul Varad πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Talactoferrin (TLF), a recombinant form of human lactoferrin (hLF), is an immunomodulatory iron‐binding glycoprotein first identified in breast milk. Its immunomodulatory functions include activation of natural killer (NK) and lymphokine‐activated killer cells and enhanc

Infusional floxuridine-based therapy for
Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma
✍ David M. Reese; Michelle Corry; Eric J. Small πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 77 KB πŸ‘ 2 views

## BACKGROUND. The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional F